ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Camptosar (Irinotecan) Avastin (Bevacizumab) EP=Moderate; FN> TherAdvMedOncol2010Sep;2(5):309-17Camptosar (Irinotecan) Vectibix (Panitumumab) EP=Moderate; FN> NEnglJMed2004;351:337-345FOLFIRI Vectibix (Panitumumab) EP=Moderate; FN=10%-20%Irinotecan 180mg/m2 D1, D15Leucovorin 400mg/m2 D1, D155-Fluorouracil 400mg/m2 IVP D1, D155-Fluorouracil 2400mg/m2 CI over 46 hours D1, D15Panitumumab 6mg/kg D1, D15q 28 Day Cycle>> BrJ<strong>Cancer</strong>2008Aug5;99(3):455-8Erbitux (Cetuximab) EP=Minimal; FN> NEnglJMed2004;351:337-345Xeloda (Capecitabine) +/- Erbitux (Cetuximab) EP=Low; FN> JClinOncol2005Feb1;23(4):792-9>> J Clin Oncol 19:4097-4106, 2001>> J Clin Oncol 26:2013-2019, 2008Vectibix (Panitumumab) EP=Minimal; FN> J Clin Oncol 25:1658-1664, 2007Stivarga (Regorafenib)Regorafenib 160mg PO D1-21q 28 Day Cycle>> J Clin Oncol 30 (suppl 4):LBA385, 2012<strong>Clinical</strong> Trial:Screen patient for clinical trial. Check www.clinicaltrials.gov for available trials.Best Supportive Care and/or Hospice:Consider supportive care options and Hospice when appropriate.Page 22 of 39© 2013 by <strong>ION</strong> <strong>Solutions</strong>. All rights reserved
Change language